Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study

Background Desmoid fibromatosis (desmoid tumor, DT) is a soft tissue neoplasm prone to recurrence despite complete surgical resection. Numerous small retrospective reports suggest that non‐cytotoxic chemotherapy using tamoxifen and sulindac may be effective for DT. We evaluated the safety and effica...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2013-07, Vol.60 (7), p.1108-1112
Main Authors: Skapek, Stephen X., Anderson, James R., Hill, D. Ashley, Henry, David, Spunt, Sheri L., Meyer, William, Kao, Simon, Hoffer, Fredric A., Grier, Holcombe E., Hawkins, Douglas S., Raney, R. Beverly
Format: Article
Language:English
Subjects:
Adolescent
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
chemotherapy
Child
desmoid-type fibromatosis
Disease-Free Survival
Female
Fibromatosis, Aggressive - drug therapy
Fibromatosis, Aggressive - mortality
Hematology
Humans
Male
Oncology
Pediatrics
sulindac
Sulindac - administration & dosage
Sulindac - adverse effects
tamoxifen
Tamoxifen - administration & dosage
Tamoxifen - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Desmoid fibromatosis (desmoid tumor, DT) is a soft tissue neoplasm prone to recurrence despite complete surgical resection. Numerous small retrospective reports suggest that non‐cytotoxic chemotherapy using tamoxifen and sulindac may be effective for DT. We evaluated the safety and efficacy of tamoxifen and sulindac in a prospective phase II study within the Children's Oncology Group. Procedures Eligible patients were
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.24457